Blood tests are ordered on a daily basis in intensive care units (ICU). There are no widely accepted guidelines for testing requirements. This study investigated the impact on ICU laboratory test costs of a multi-strategy change in practice involving routine blood testing. A single centre, prospective, interventional study using historical controls was undertaken to investigate the impact of ICU specialist authorisation of high-volume routine tests on ICU laboratory test costs. Prior to commencement of the study, ICU nursing and junior ICU doctors were able to order tests. During the six-month intervention period, the ICU specialists authorised routine blood tests. Adverse events related to not performing blood tests were also recorded. Overall ICU laboratory test costs decreased by 12.3% over the six months (P=0.0022 versus historical control) with a mean compliance of 51% with the test authorisation protocol. The costs of frequently ordered tests (classified as high-volume) decreased by 20% (P=0.0022 versus historical control). These accounted for an average of 54 ± 3% of the overall ICU blood test costs (blood gas analyses 17%, simple chemistry tests consisting of electrolytes, liver function, calcium, phosphate, magnesium 14%, coagulation 12% and full blood count 11%). Two protocol-related adverse events were recorded and judged as minor and were resolved by ordering tests during the day. No adverse patient outcomes resulted from these two events. Blood testing authorisation by an ICU specialist was associated with significant cost savings in ICU and no adverse patient outcomes.
Background
Blood tests are often ordered on a daily basis in intensive care units (ICUs) and there are no widely accepted guidelines for testing requirements.
A survey by Flabouris et al 1 concluded that blood tests are routinely ordered in 87% of ICUs in Australasia. Of these, 46% of units have specific guidelines and only 37% followed ICU specialist consultation. Losfina et al 2 examined an on-demand strategy for routine test orders and achieved a 24% reduction in orders over a one-week period in a 15-bed medical and surgical ICU. Cismondi et al 3 used fuzzy mathematics and artificial intelligence to predict the benefit of future laboratory tests in patients with gastrointestinal bleeding and projected a 50% reduction in future tests.
Ritchie et al 4 concluded that encouraging junior doctors to use an e-learning tool such as iNvestigate reduced laboratory test costs by A$66,000 in six clinical departments over a sixweek period in a major tertiary hospital. In a study by Seguin et al 5 , the ordering of blood gas analysis and electrolytes in the ICU was reduced by 22% by providing information about the costs of tests.
Mehari et al 6 concluded that written guidelines remained effective even three years after implementation in reducing the costs of laboratory tests by 4% in postoperative cardiac surgical patients and by 5.6% in general intensive care patients. The 2012 National Coalition of Public Pathology report 7 identified several strategies to reduce costs including the involvement of senior clinicians in ordering tests, rather than delegation to junior colleagues.
The ICU at Liverpool Hospital is a multidisciplinary unit and was funded to operate 30 beds during the study period in 2015. Sydney South West Pathology Service provided laboratory and specimen collection services for the local health district. The routine morning blood tests were ordered on the previous day by the ICU registrars, resident medical officers and occasionally by ICU nurses. Although the ICU specialists supervised day-to-day patient management, they may not have been involved in the ordering of all pathology tests.
The monthly average cost of laboratory tests for ICU was A$210,000 from January to June 2014. High-volume blood tests (i.e. tests ordered on a daily basis or more frequently, categorised as A-D in Table 1 ) contributed the majority of the total laboratory cost (>55%), while add-on tests accounted only for 3% of total cost.
Historical data from January to June 2014 were analysed to assess the feasibility and decide the objectives of this study, aimed at investigating the impact of a multi-strategy change regarding high-volume blood test orders to reduce overall ICU laboratory test costs. Strategies included senior clinician authorisation of tests, rationalisation of high-volume test orders, displaying test costs at the bedside and education of staff on the relevance of tests in a clinical context.
Primary and secondary objectives
The primary objective of this study was to lower overall pathology costs by 10% over six months. The secondary objectives were to evaluate cost reductions in each subgroup (A-D, Table 1 ) of high-volume tests and to monitor adverse events related to a test not being performed. 
Methods

Ethics approval and funding
Study design
This was a single centre prospective interventional study in a multidisciplinary ICU using historical monthly and total laboratory test cost data from January to June 2014. All adult patients (≥18 years of age) admitted to the ICU over a sixmonth period from 1 March to 31 August 2015 were included in the study.
Each patient had a RCPA-ICU study clinical pathology test authorisation form kept in a bedside folder. The back of this form had a provision to authorise any additional high-volume tests needed during the day and these were authorised as required (Appendix 1).
A new ICU day starts at 2400 hours in our ICU. On the day of admission (Day 0), tests were performed as per the ICU team and the patient's admitting team. Beginning the first day after admission to ICU, the high-volume tests required for the next and subsequent days were authorised by the ICU specialist on the bedside paper-based form during the evening ward round along with the team. The ICU registrar translated the consultant-authorised tests onto our pathology electronic ordering system (PowerChart®), before they completed the shift for the day. After the ICU specialist left the hospital, the onsite ICU senior registrars and registrars authorised tests for the next day for all late evening admissions between 1800 and 2400. The costs of these test(s) and guidelines for ordering were provided to them. No ICU nurses were authorised to order tests during the study period. The study was concluded once the patient left ICU or died in ICU. Education sessions were conducted prior to the commencement of the study on 1 March 2015, with monthly updates until the completion of the study. These sessions included education on preventing repetition of tests over short time periods, the relevance of testing in the clinical context and the cost of the tests.
Adverse event monitoring
Any adverse event, as judged by the ICU specialist or admitting specialists, related to not performing a blood test was recorded on a separate form which also included a severity grading based on the time required for resolution of the event (Appendix 2). Bedside nurses and ICU junior medical staff were also encouraged to report any adverse events to the specialists to enhance the accuracy of reporting.
Data collection
The ICU length-of-stay, number of patients per month, Acute Physiology and Chronic Health Evaluation III severity score, adverse events, number of high-volume tests authorised for the next day and the add-on tests during the day were recorded. A monthly summary of the actual number of tests performed and their costs were obtained from Sydney South West Pathology Service.
Data analysis
The historical laboratory test costs for March to August 2014 (control) were compared with costs for March to August 2015 (study period). The final cost analysis during the study period was based upon the laboratory tests ordered from 1 March 2015 to midnight 31 August 2015, the latter being the study completion time and date. The pathology billing date was used to calculate monthly cost data, including any private and compensable patients. Standardised daily ICU cost was calculated as the total monthly laboratory cost divided by the median total ICU length-of-stay for each month.
Protocol compliance was calculated as the actual number of tests authorised, divided by the total number of tests performed by the laboratory and expressed as a percentage.
Statistics
Results are reported as median with the interquartile range, as proportions (percentage) or absolute count/cost. The pre-and post-intervention groups of monthly data over six months were compared using the Mann-Whitney test. A P-value less than 0.05 was considered significant. All statistical analyses were performed using GraphPad PRISM v6.0 (GraphPad Software Inc., La Jolla, CA, USA).
Results
For ease of description, the data from 2014 are referred to as 'historical' and the 2015 data are referred to as 'study' results.
Demographics
More patients were admitted to ICU in the 2015 study period compared to the 2014 historical period (P=0.028) but the Acute Physiology and Chronic Health Evaluation III scores, the ICU length-of-stay and the total ICU days were not statistically different (Table 2) .
Primary objective
The overall laboratory costs for March to August 2015 were reduced by 12.30% compared to March to August 2014 (P=0.0022) ( Tables 3 and 4) .
Secondary objectives
The cost of high-volume tests was reduced by 20% in 2015 compared to 2014 (P=0.0022). Blood gas analyses contributed most to the overall cost (17%) followed by simple chemistry (14%), coagulation tests (12%) and full blood counts (11%). There was a 4.8% reduction in the contribution Tables 3 and 4) . During the study period, the mean protocol compliance for authorisation of laboratory tests for the next day including specialist authorisation during working hours and senior registrar/registrar authorisation between 1800 and 2400 hours (for 23% of afterhours ICU admissions) was calculated to be around 51% (Table 5 ). This was derived from the total number of tests authorised by the medical team divided by the actual number of tests performed by the laboratory and expressed as a percentage.
Two study protocol-related adverse events were recorded and judged as minor (minor delays in daily plans) and were resolved by ordering tests during the day. No adverse patient outcomes resulted from these two events.
Discussion
This pragmatic study was performed over six months during the three seasons of late summer, autumn and winter on the Australian east coast to cover seasonal variability of severity of illness. Our study used unique methodology with a combination of practical strategies including ICU specialist authorisation of routine high-volume tests, displaying the costs of tests at the bedside, education of staff regarding the relevance of these tests in a clinical context and monitoring adverse events when tests were not authorised by the specialist.
With the above strategies, the study demonstrated a significant reduction in the overall ICU laboratory test costs with no clinically significant adverse events. The overall laboratory cost reduction of 12.3% was achieved with an observed protocol compliance of 51%. This compliance rate may indicate room for further improvement to achieve more cost reductions. Our results may reflect that junior medical staff or nurses often order tests routinely or based on their interpretation of their specialist's expectation. However, transferring decision-making to the most senior person managing patient care resulted in the reduction of blood tests in our study. Experienced intensivists generally are aware that daily routine blood tests are not required in stable ICU patients and this study provides objective evidence to support this.
Coagulation tests contributed to over 12% of total cost and potential cost savings are achievable if they are ordered as clinically indicated. Blood gas analyses in ICU were a significant contribution to total cost (17%). Not using repeated blood gas analysis to check potassium levels after administering potassium or to guide weaning of the inspiratory fraction of oxygen in a stable ventilated patient were examples of significant potential savings.
Rationalised ordering of tests may also help to reduce the need for add-on test orders (5% of test orders in our study) during the day, further reducing the total cost. This strategy for test ordering can potentially free up nursing time, reduce the use of disposables, reduce processing fees and reduce blood test-induced anaemia in the ICU.
Limitations
This study is limited by its single centre study design within a limited time period. It illustrated the financial impact in a tertiary public hospital ICU based on the pathology billing setup in New South Wales Health. The design and outcomes need to be confirmed in a larger multicentre study including both private and public hospitals in different states and territories with different pathology billing arrangements. The study protocol focused on the more predictable highvolume tests only to rationalise orders, and did not include other tests in the ICU that are either mandatory or cannot be predicted. We attempted to monitor adverse events in this study and only two minor events were reported. Underreporting of events is possible for a number of reasons (e.g. reluctance to report, or failure to recognise an adverse event), but it appears that there were no serious adverse outcomes. Also, we did not precisely record the portion of tests authorised by senior registrars/registrars, which may have enhanced the accuracy of protocol compliance (51% in our study).
Conclusions
Our study provides guidance for a rational protocol to address the costs of routine blood test ordering in the ICU. The study results support that clinically stable patients do not require daily blood tests. Senior medical staff should provide active guidance to junior colleagues regarding ordering of blood tests only when clinically relevant. The awareness of costs involved in routine blood testing should be improved.
